Thomas McGee, MD
Rheumatology · Mobile, ALNPI 1942253737
Payments from drug & device makers
Across 687 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- AbbVie$3K
- GSK$1K
- Johnson & Johnson$602
- UCB, Inc.$403
- Lilly USA, LLC$378
- plus $3K from 30 others
What the payments were for
- Food & beverage$11,73199%
- Education$1551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 223 | $3,321 |
| AbbVie | 167 | $3,259 |
| GSK | 75 | $1,275 |
| Johnson & Johnson(2 entities) | 28 | $602 |
| UCB, Inc. | 24 | $403 |
| Lilly USA, LLC | 23 | $378 |
| Pfizer | 20 | $331 |
| Mallinckrodt Hospital Products Inc. | 11 | $302 |
| Bayer | 10 | $235 |
| AstraZeneca(2 entities) | 14 | $233 |
| Genentech USA, Inc. | 15 | $188 |
| Aurinia Pharma U.S., Inc. | 9 | $187 |
| Radius Health, Inc. | 10 | $175 |
| Novartis | 7 | $136 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $136 |
| Sanofi | 4 | $77 |
| Sandoz | 5 | $74 |
| Boehringer Ingelheim | 4 | $62 |
| Antares Pharma, Inc. | 3 | $55 |
| ANI Pharmaceuticals, Inc. | 2 | $46 |
| Actelion Pharmaceuticals US, Inc. | 3 | $46 |
| Organon | 2 | $41 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $39 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Fresenius Kabi USA, LLC | 2 | $31 |
| E.r. Squibb & Sons, L.L.C. | 2 | $31 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Pacira Therapeutics, Inc. | 1 | $24 |
| Sanofi Pasteur Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Invivyd Inc | 1 | $21 |
| Upsher-smith Laboratories LLC | 1 | $20 |
| Eisai Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Merck | 1 | $13 |
| Assertio Therapeutics, Inc. | 1 | $11 |
How this compares
$11,886 in reported general payments places this provider in the 55th percentile of 90 rheumatology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 208 | $1,757,349 |
| RinvoqUpadacitinib | 150 | $963,226 |
| Humira(Cf) PenAdalimumab | 100 | $763,709 |
| Enbrel MiniEtanercept | 52 | $438,173 |
| XeljanzTofacitinib Citrate | 42 | $243,621 |
| BenlystaBelimumab | 48 | $223,253 |
| KevzaraSarilumab | 42 | $178,471 |
| SimponiGolimumab | 17 | $155,196 |
| Actemra ActpenTocilizumab | 54 | $153,558 |
| OtezlaApremilast | 16 | $117,152 |
| JardianceEmpagliflozin | 171 | $113,906 |
| RybelsusSemaglutide | 98 | $111,650 |
| EliquisApixaban | 139 | $105,169 |
| Humira PenAdalimumab | 14 | $93,799 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 13 | $93,779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $3,259 | $963,226150 claims |
| PfizerXeljanz, Eliquis | $331 | $348,789181 claims |
| GSKBenlysta | $1,275 | $223,25348 claims |
| SanofiKevzara | $77 | $178,47142 claims |
| Johnson & JohnsonSimponi, Xarelto | $602 | $167,56031 claims |
| AmgenOtezla, Rayos | $3,321 | $150,75929 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $62 | $119,466182 claims |
| UCB, Inc.Cimzia (2 Pack) | $403 | $89,87216 claims |
| AstraZenecaFarxiga | $233 | $47,86462 claims |
| MerckJanuvia, Janumet Xr, Belsomra | $13 | $31,54547 claims |
| Lilly USA, LLCTrulicity | $378 | $27,18821 claims |
| BayerKerendia | $235 | $16,45623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 90 rheumatology providers in Alabama.
Other rheumatology in Mobile
- Gino DivittorioMobile$139K
- Deepak KumarMobile$48K
- Teresa OglesbyMobile$11K
- Yanming XingMobile$11K
- James LawrenceMobile$10K
- Sonia SavaniMobile$10K
- Thomas MyersMobile$9K
- Hamdy AhmedMobile$5K
- Jeffrey CurtisBirmingham$17.6M
- Kenneth SaagBirmingham$8.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.